Nucynta ER (Tapentadol HCl) Patent Expiration, LOE Window & CMS Spending
Nucynta ER (Tapentadol HCl) by Collegium: FDA Orange Book LOE 2029-03-22, 2 AB generics, $55.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Collegium |
| FDA Application & Pathway | N200533 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2029-03-22 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $55.2M |
| 2024 Medicare Part D Spend | $47.7M |
| 2024 Medicaid Spend | $7.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |